Genedata, a leading provider of advanced software solutions for drug discovery and life science research, has announced that Ono Pharmaceutical Co., Ltd.. (Ono) extended its Genedata collaboration with a license of Genedata Expressionist for Mass Spectrometry. Ono is a leading R&D-oriented international pharmaceutical company, which provides treatments for oncological and cardiovascular diseases. The Genedata Expressionist system, an enterprise and comprehensive platform for omics data management, will be used by Ono to further strengthen its targeted proteomics and metabolomics research.
"Our daily research demands accurate mass profiling analysis as well as powerful MRM capabilities for effective quantitative analysis," noted a spokesperson for the Tsukuba Research Institute at Ono. "Genedata Expressionist for Mass Spectrometry supports our proteomics and metabolomics research with a sophisticated data analysis platform that can process chromatograms ranging from 2MB to over 1GB. And, the system's ability to integrate data from a variety of instruments is a valuable benefit to us. Finally, with Genedata Expressionist we can rely on superior algorithms that generate clinically relevant biomarkers supporting efficient research processes."
Experimental designs of molecular profiling studies in the life sciences are continually growing in complexity and size. Genedata Expressionist analyzes and manages genomic, transcriptomics, proteomics, metabolomics, and epigenomics data from leading technologies including next-generation sequencing, high-density microarrays, RT-PCR, and other genomic tools. Additionally, Genedata Expressionist enables integrated analysis and management of all major mass spectrometry (MS) profiling applications including a comprehensive solution for proteomic, metabolomics, and lipidomics data from all major MS technologies. With robust support of MRM data, the system's innovative capabilities include:
"We are proud of our collaboration with Ono, one of the world's leading pharmaceutical companies providing innovative drug therapies," said Dr. Othmar Pfannes, CEO of Genedata. "With Genedata Expressionist and its support of innovative technologies such as MS and next-generation sequencing, we provide an integrative computational platform that supports customers such as Ono who are pioneering novel therapies. And, we are committed to continuous innovation by expanding the scope Genedata Expressionist applications in areas such as molecular diagnostics and personalized healthcare."